# Bristol Myers Raises Revenue Outlook as Newer Medicines Drive Growth

Quarterly sales increased 7%, while earnings declined with acquisition-related research costs and licensing income affecting comparisons.

By Will Langan | 24X7 News
Published: 2026-10-29T14:02:48.715Z
Updated: 2026-10-29T14:02:48.715Z
Section: Business
Format: News
Canonical: https://24x7news.us/articles/bristol-myers-third-quarter-results-october-29-2026

Bristol Myers Squibb raised its annual revenue outlook October 29 after third-quarter sales increased 7% to $13.069 billion.

The company now forecasts 2026 revenue of $49.75 billion–$50.25 billion and adjusted earnings of $6.35–$6.55 per share.

Quarterly earnings under standard accounting rules were $1.05 per share, down from $1.08 a year earlier. Adjusted earnings fell to $1.35 from $1.63.

Both current-quarter measures included a net negative impact of 58 cents per share from acquired in-process research and development charges and licensing income. The comparable impact a year earlier was 20 cents.

Sales in the company’s Growth Portfolio rose 12% to $7.7 billion, with contributions from Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag. Legacy Portfolio sales increased 1% to $5.4 billion, as Eliquis growth partly offset generic competition affecting other products.

U.S. revenue increased 9% to $9.1 billion. International sales rose 3% to $4 billion.

The full-year adjusted earnings forecast includes a net 60-cent impact from acquired research charges and licensing income. Guidance remains a projection, and adjusted earnings exclude specified items included in reported results.

Sources:
Bristol Myers Squibb — October 29 Earnings Release in Form 8-K: https://www.stocktitan.net/sec-filings/BMY/8-k-bristol-myers-squibb-co-reports-material-event-e60c369ad9da.html

## Sources
- Bristol Myers Squibb — October 29 Earnings Release in Form 8-K: https://www.stocktitan.net/sec-filings/BMY/8-k-bristol-myers-squibb-co-reports-material-event-e60c369ad9da.html